Psychedelics

New neuroscience research suggests the cerebral cortex acts as the brain’s hourglass

2021-09-18 The Conversation Staff

No one can stay awake forever. While we’re awake, our need for sleep gradually increases.

Study on MDMA for Traumatic Brain Injury Boosted By $1.5M Donation

2021-09-17 Benjamin M. Adams

Wesana Health committed to fund a MAPS study on MDMA for traumatic brain injury.

The Two-Pronged Psychedelics Solution To The Opioid Crisis

2021-09-16 PSW Editor

Clinical research is rapidly advancing in using psychedelic drugs to treat opioid addiction. However, psychedelics can also reduce opioid-related deaths as a SUBSTITUTE for opioids.

AdvisorShares Launches Psychedelics ETF (Ticker: PSIL)

2021-09-16 PSW Editor

AdvisorShares' new psychedelics ETF commences trading today on the NYSE Arca Exchange (symbol "PSIL") with a focus on small-cap psychedelic stocks.

California Activists Cleared To Collect Signatures For Psilocybin Legalization Ballot Initiative

2021-09-16 Kyle Jaeger

California activists are now cleared to begin collecting signatures for an initiative to legalize psilocybin mushrooms in the state.

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

2021-09-15 PSW Editor

Compass Pathways acquires an unspecified IP portfolio of psychedelic and emphathogenic substances.

House Could Vote On Psychedelics Research For Military And Marijuana Banking As Part Of Defense Bill

2021-09-15 Kyle Jaeger

House lawmakers have introduced a series of drug policy-related amendments to defense legislation, including proposals to facilitate research on the benefits of psychedelics for active duty military personnel and to protect banks that service state-legal marijuana businesses.

Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline

2021-09-14 PSW Editor

Wesana looks to expand its TBI-based psychedelics research into MDMA, with a new research partnership with MAPS.

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression

2021-09-14

Atai affiliate, Perception Neuroscience is commencing a Phase 2a clinical trial of an R-ketamine medication for the treatment of depression.

Detroit Voters Will Decide On Psychedelics Decriminalization Ballot Measure In November

2021-09-14 Kyle Jaeger

Detroit could become one of the next Michigan cities to decriminalize psychedelics, with the reform proposal making the local ballot for this November.

Why Psychedelic Medicine Cures Will Have Greater Profit Potential Than Big Pharma Bandaids

2021-09-13 Jeff Nielson

Big Pharma's business model for drug development is all about maximizing profits, not health. Psychedelic medicine can maximize profits AND health.

atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression

2021-09-10 PSW Editor

Atai Life Sciences seeks to integrate digital therapeutics into ketamine-based treatment for TRD, via its digital therapeutic platform, Introspect Digital Therapeutics.